TriSalus Life Sciences Inc (NAS:TLSI)

Q3 2025 TriSalus Life Sciences Inc Earnings Call Transcript

Nov 13, 2025 / 09:30 PM GMT

Release Date Price: $4.39 (-0.68%)

Transcript 10-Q8-K

Key Points

Positve

TriSalus Life Sciences Inc (TLSI) reported a strong third quarter with revenues of $11.6 million, marking a 57% increase over the prior year and a 3% sequential gain.
The company successfully expanded its TriNA platform by launching the TriNA Flex infusion system and advancing new clinical applications.
TriSalus Life Sciences Inc (TLSI) simplified its capital structure through the successful completion of an exchange offer and consent solicitation for preferred stock.
The company reaffirmed its 50% revenue growth guidance, reflecting strong confidence in its growth momentum and market opportunities.
TriSalus Life Sciences Inc (TLSI) is expanding its product portfolio, which broadens its addressable market and strengthens physician adoption.

Negative

The gross margin for the quarter decreased to 84% from 86% in the prior year, primarily due to lower manufacturing efficiency associated with newly launched products.
Research and development expenses increased to $5.2 million, up from $4.2 million in the third quarter of 2024, due to a one-time charge related to the closure of clinical studies.
Operating loss for the quarter was $9 million, compared to $8.7 million in the prior year, driven by one-time charges and non-cash stock-based compensation acceleration.
The company is extending its timeline to reach EBITDA positive and cash flow breakeven due to increased commercial investment.
There are still challenges with the adoption of new reimbursement codes, which are causing some bumps in the process of expanding the use of their technology.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

TLSI.OQ - TriSalus Life Sciences Inc
Q3 2025 TriSalus Life Sciences Inc Earnings Call
Nov 13, 2025 / 09:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good afternoon and welcome to Trialis Life Science 3rd quarter 2025 earnings conference call. Currently all participants are on a listen-only mode. Following management's prepared remarks, we will hold a question-and-answer session. As a reminder, this call is being recorded for replay purposes. I will now turn the call over to Jeremy Pfeffer, managing director with Flysa Advisors. Please go ahead, sir.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you, operator, and thank you all for participating in today's call. Joining me today from TriSalis Life Sciences

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.